These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11101051)

  • 1. Didanosine once daily: potential for expanded use.
    Pollard RB
    AIDS; 2000 Nov; 14(16):2421-8. PubMed ID: 11101051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD; Wong WM; Keruly JC; McArthur JC
    AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
    Cepeda JA; Wilks D
    AIDS; 2000 Feb; 14(3):332-3. PubMed ID: 10716516
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
    Barreiro P; Soriano V; Valencia E; Díaz B; González-Lahoz J
    AIDS; 2001 Dec; 15(18):2469-70. PubMed ID: 11774839
    [No Abstract]   [Full Text] [Related]  

  • 10. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
    Moreno S; Hernández B; Dronda F
    Drugs; 2007; 67(10):1441-62. PubMed ID: 17600392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.
    Raffi F; Reliquet V; Auger S; Besnier JM; Chennebault JM; Billaud E; Michelet C; Perre P; Lafeuillade A; May T; Billaudel S
    AIDS; 1998 Oct; 12(15):1999-2005. PubMed ID: 9814868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
    Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
    AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.
    Reynes J; Denisi R; Massip P; Izopet J; Pellegrin I; Segondy M
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):103-5. PubMed ID: 10534154
    [No Abstract]   [Full Text] [Related]  

  • 18. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM; Balfour JA
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-retroviral treatment. Treatment modification: toxicity management].
    Ocaña I; Laguna F; Pulido F; Bascuñana A
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():31-5. PubMed ID: 9053025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.